Adding antiandrogen to castration improves survival
May 1st 2005Orlando, FL--What are the benefits of combining castration with a nonsteroidal antiandrogen in the treatment of advanced prostate cancer? Laurence Klotz, MD, of the University of Toronto, has found a high probability that bicalutamide (Casodex), 50 mg/day, plus castration provides a survival advantage over castration alone.
Estrogen receptor modulator prevents PCa in some men
May 1st 2005Orlando, FL--Testosterone's effect on the development and progression of BPH and prostate cancer is well known, but a group of University of Tennessee researchers has been focusing on testosterone's less frequently studied "partner in crime"—estrogen.
Phase II trials of prostate Ca vaccine promising
May 1st 2005Orlando, FL--A genetically modified vaccine has demonstrated immunogenicity and clinical activity in hormone-refractory prostate cancer patients with metastatic disease, researchers reported in a poster presentation at the 2005 Multidisciplinary Prostate Cancer Symposium.
Latency time about 5 minutes shorter in PE sufferers
April 21st 2005The average intravaginal ejaculatory latency time of premature ejaculation sufferers is 1.8 minutes, versus 7.3 minutes in men without PE, according to a large epidemiologic study published in The Journal of Sexual Medicine (2005; 2:358).
Latency time about 5 minutes shorter in PE sufferers
April 21st 2005The average intravaginal ejaculatory latency time of premature ejaculation sufferers is 1.8 minutes, versus 7.3 minutes in men without PE, according to a large epidemiologic study published in The Journal of Sexual Medicine (2005; 2:358).
Investigational OAB agent shows significant improvements in phase III trial
April 21st 2005An agent under investigation for treatment of overactive bladder demonstrated statistically significant improvements over placebo in phase III trials, according to Schwarz Pharma, which is developing the drug, fesoterodine.
Indian urologists to hold first educational session concurrent with AUA meeting
April 8th 2005The Indian American Urological Association (IAUA) said it will hold its educational program under the auspices of AUA for the first time next month. The program is scheduled for May 21 at the Marriott Riverwalk, San Antonio, TX.
Some men may experience vision loss after taking PDE-5 inhibitor
April 8th 2005Within 36 hours after ingesting sildenafil citrate (Viagra) for erectile dysfunction, some men have nonarteritic anterior ischemic optic neuropathy (NAION), described as "stroke of the eye," according to a report of seven cases published in the Journal of Neuro-ophthalmology (2005; 25:9-13).
Study will test testosterone gel in hypogonadal men with diabetes
April 8th 2005Testosterone gel (AndroGel) 1% will be evaluated for its efficacy and safety as an adjunct to oral hypoglycemic therapy in men with type 2 diabetes and hypogonadism, according to its manufacturer, Solvay Pharmaceuticals, Inc.
Two-drug combination shows positive results in men with ED
April 8th 2005A clinical study evaluating the effect of co-administration of an investigational intranasal agent PT-141 and sildenafil citrate (Viagra) shows positive results in patients with erectile dysfunction, according to researchers from Palatin Technologies Inc. and King Pharmaceuticals Inc.
Injectable LHRH agonist now available nationwide
April 8th 2005The FDA has approved triptorelin pamoate for injectable suspension (Trelstar Depot, 3.75 mg, and Trelstar LA 11.25 mg). The sustained-release, 1- and 3-month intramuscular injectable formulations are now available nationwide for the palliative treatment of advanced prostate cancer when orchiectomy or estrogen administration are either not indicated or are unacceptable to the patient.
Hormonal therapy post-radiation increases survival in PCa patients
April 8th 2005Androgen suppression immediately after radiotherapy in high-risk prostate cancer patients reduces the disease progression and significantly improves survival, according to long-term data published in the International Journal of Radiation Oncology*Biology*Physics (2005; 61:1285-90).
Careful evaluation key in patients with refractory OAB
April 1st 2005Philadelphia--Urologists who manage patients with overactive bladder are challenged not only with choosing from a growing list of pharmacologic treatment options, but also with the prospect that some patients may not respond to oral anticholinergic treatment at all. In these patients with "refractory detrusor overactivity," it is important to realize that a number of factors mitigate against successful therapy, said Roger R. Dmochowski, MD, professor of urology at Vanderbilt University Medical Center, Nashville, TN.
Bladder cancer test boosts accuracy of cystoscopy
April 1st 2005Houston--Nuclear matrix protein 22 (NMP22) is to bladder cancer as PSA is to prostate cancer, perhaps better. That is the implication of a recently published, prospective, multi-institution study showing the point-of-care NMP22 assay (BladderChek, Matritech, Newton, MA) has a sensitivity of 55.7% and a specificity of 85.7%. In contrast, cytology was found to have lower sensitivity (15.8%) but higher specificity (99.2%).
Debate rages over Medicare coverage of sexual dysfunction drugs
April 1st 2005Washington--A controversy is brewing over whether Medicare should pay for erectile dysfunction drugs, which boiled over in the midst of heated discussions over the cost of the new Medicare drug benefit. Now estimated at $720 billion, the expected cost of the program is nearly double the government's original 2003 projections.